Seminars in Oncology
Volume 31, Issue 1 , Pages 90-119 , February 2004

Apoptosis in cancer—implications for therapy

  • Henning Schulze-Bergkamen

      Affiliations

    • Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany
    • ,
  • Peter H Krammer

      Affiliations

    • Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany
    • Corresponding Author InformationAddress reprint requests to Peter H. Krammer, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany

References 

  1. Kerr JF, Wyllie AH, Currie AR. Apoptosis (A basic biological phenomenon with wide-ranging implications in tissue kinetics). Br J Cancer. 1972;26:239–257
  2. Vaux DL. Caspases and apoptosis—Biology and terminology. Cell Death Differ. 1999;6:493–494
  3. Krammer PH. CD95’s deadly mission in the immune system. Nature. 2000;407:789–795
  4. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell. 1997;88:347–354
  5. Baumann S, Krueger A, Kirchhoff S, et al.  Regulation of T cell apoptosis during the immune response. Curr Mol Med. 2002;2:257–272
  6. Wyllie AH, Kerr JF, Currie AR. Cell death (The significance of apoptosis). Int Rev Cytol. 1980;68:251–306
  7. Savill JS, Henson PM, Haslett C. Phagocytosis of aged human neutrophils by macrophages is mediated by a novel “charge-sensitive” recognition mechanism. J Clin Invest. 1989;84:1518–1527
  8. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784–788
  9. Fadok VA, Bratton DL, Konowal A, et al.  Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101:890–898
  10. Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol. 1998;10:545–551
  11. Tartaglia LA, Ayres TM, Wong GH, et al.  A novel domain within the 55 kd TNF receptor signals cell death. Cell. 1993;74:845–853
  12. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem. 1993;268:10932–10937
  13. Schulze-Osthoff K, Ferrari D, Los M, et al.  Apoptosis signaling by death receptors. Eur J Biochem. 1998;254:439–459
  14. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol. 2000;32:1123–1136
  15. Leithauser F, Dhein J, Mechtersheimer G, et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69:415–429
  16. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314–317
  17. Suda T, Takahashi T, Golstein P, et al.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169–1178
  18. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med. 1994;179:873–879
  19. Takahashi T, Tanaka M, Brannan CI, et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969–976
  20. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies (Integrating mammalian biology). Cell. 2001;104:487–501
  21. Tanaka M, Suda T, Haze K, et al.  Fas ligand in human serum. Nat Med. 1996;2:317–322
  22. Suda T, Hashimoto H, Tanaka M, et al.  Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045–2050
  23. Schneider P, Bodmer JL, Holler N, et al.  Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem. 1997;272:18827–18833
  24. Krammer PH. CD95(APO-1/Fas)-mediated apoptosis (Live and let die). Adv Immunol. 1999;71:163–210
  25. Schneider P, Holler N, Bodmer JL, et al.  Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205–1213
  26. Wiley SR, Schooley K, Smolak PJ, et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682
  27. Pan G, O’Rourke K, Chinnaiyan AM, et al.  The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111–113
  28. Pan G, Ni J, Wei YF, et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815–818
  29. Walczak H, Degli-Esposti MA, Johnson RS, et al.  TRAIL-R2 (A novel apoptosis-mediating receptor for TRAIL). EMBO J. 1997;16:5386–5397
  30. Trauth BC, Klas C, Peters AM, et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245:301–305
  31. Kischkel FC, Hellbardt S, Behrmann I, et al.  Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579–5588
  32. Walczak H, Sprick MR. Biochemistry and function of the DISC. Trends Biochem Sci. 2001;26:452–453
  33. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7:313–319
  34. Scaffidi C, Fulda S, Srinivasan A, et al.  Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675–1687
  35. Luo X, Budihardjo I, Zou H, et al.  Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481–490
  36. Algeciras-Schimnich A, Shen L, Barnhart BC, et al.  Molecular ordering of the initial signaling events of CD95. Mol Cell Biol. 2002;22:207–220
  37. Chan FK, Chun HJ, Zheng L, et al.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351–2354
  38. Huang DC, Strasser A. BH3-only proteins—Essential initiators of apoptotic cell death. Cell. 2000;103:839–842
  39. Wei MC, Lindsten T, Mootha VK, et al.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000;14:2060–2071
  40. Li P, Nijhawan D, Budihardjo I, et al.  Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–489
  41. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770–776
  42. Du C, Fang M, Li Y, et al.  Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42
  43. Susin SA, Lorenzo HK, Zamzami N, et al.  Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441–446
  44. Evan G, Littlewood T. A matter of life and cell death. Science. 1998;281:1317–1322
  45. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6:513–519
  46. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases (Structure, activation, substrates, and functions during apoptosis). Annu Rev Biochem. 1999;68:383–424
  47. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol. 1999;17:781–828
  48. Marguet D, Luciani MF, Moynault A, et al.  Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey. Nat Cell Biol. 1999;1:454–456
  49. Fadok VA, Chimini G. The phagocytosis of apoptotic cells. Semin Immunol. 2001;13:365–372
  50. Berndt C, Mopps B, Angermuller S, et al.  CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc Natl Acad Sci. 1998;USA 95:12556–12561
  51. Borner C, Monney L. Apoptosis without caspases (An inefficient molecular guillotine?). Cell Death Differ. 1999;6:497–507
  52. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA. 1996;93:14559–14563
  53. Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA. 2000;97:14376–14381
  54. Muller M, Wilder S, Bannasch D, et al.  p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188:2033–2045
  55. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 2000;19:1735–1743
  56. Krueger A, Baumann S, Krammer PH, et al.  FLICE-inhibitory proteins (Regulators of death receptor-mediated apoptosis). Mol Cell Biol. 2001;21:8247–8254
  57. Krueger A, Schmitz I, Baumann S, et al.  Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem. 2001;276:20633–20640
  58. Varadhachary AS, Edidin M, Hanlon AM, et al.  Phosphatidylinositol 3′-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95. J Immunol. 2001;166:6564–6569
  59. Green DR. Apoptosis. Death deceiver. Nature. 1998;396:629–630
  60. Cory S, Adams JM. The Bcl2 family (Regulators of the cellular life-or-death switch). Nat Rev Cancer. 2002;2:647–656
  61. Kaufmann T, Schlipf S, Sanz J, et al.  Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer membrane. J Cell Biol. 2003;160:53–64
  62. Jurgensmeier JM, Xie Z, Deveraux Q, et al.  Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA. 1998;95:4997–5002
  63. Narita M, Shimizu S, Ito T, et al.  Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA. 1998;95:14681–14686
  64. Saito M, Korsmeyer SJ, Schlesinger PH. BAX-dependent transport of cytochrome c reconstituted in pure liposomes. Nat Cell Biol. 2000;2:553–555
  65. Marsden VS, O’Connor L, O’Reilly LA, et al.  Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature. 2002;419:634–637
  66. Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol. 2003;5:28–37
  67. Salvesen GS, Duckett CS. IAP proteins (Blocking the road to death’s door). Nat Rev Mol Cell Biol. 2002;3:401–410
  68. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  69. Verhagen AM, Ekert PG, Pakusch M, et al.  Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43–53
  70. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9:459–470
  71. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54
  72. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol. 1992;10:785–807
  73. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348
  74. Green DR, Evan GI. A matter of life and death. Cancer Cell. 2002;1:19–30
  75. Evan GI, Wyllie AH, Gilbert CS, et al.  Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119–128
  76. Bissonnette RP, Echeverri F, Mahboubi A, et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 1992;359:552–554
  77. Harrington EA, Bennett MR, Fanidi A, et al.  c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994;13:3286–3295
  78. Sabbatini P, Lin J, Levine AJ, et al.  Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 1995;9:2184–2192
  79. Lukashev ME, Werb Z. ECM signaling (Orchestrating cell behaviour and misbehaviour). Trends Cell Biol. 1998;8:437–441
  80. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285:1028–1032
  81. Khwaja A, Rodriguez-Viciana P, Wennstrom S, et al.  Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997;16:2783–2793
  82. Grossmann J. Molecular mechanisms of “detachment-induced apoptosis—anoikis”. Apoptosis. 2002;7:247–260
  83. Puthalakath H, Huang DC, O’Reilly LA, et al.  The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell. 1999;3:287–296
  84. Puthalakath H, Villunger A, O’Reilly LA, et al.  Bmf (A proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis). Science. 2001;293:1829–1832
  85. Oulton R, Harrington L. Telomeres, telomerase, and cancer (Life on the edge of genomic stability). Curr Opin Oncol. 2000;12:74–81
  86. Hahn WC, Stewart SA, Brooks MW, et al.  Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;5:1164–1170
  87. Zhang X, Mar V, Zhou W, et al.  Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999;13:2388–2399
  88. Franke TF, Yang SI, Chan TO, et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727–736
  89. Datta SR, Dudek H, Tao X, et al.  Akt phosphorylation of BAD couples survival signals to the cell-ntrinsic death machinery. Cell. 1997;91:231–241
  90. Tanno S, Mitsuuchi Y, Altomare DA, et al.  AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001;61:589–593
  91. Datta SR, Brunet A, Greenberg ME. Cellular survival (A play in three Akts). Genes Dev. 1999;13:2905–2927
  92. Stambolic V, Mak TW, Woodgett JR. Modulation of cellular apoptotic potential (Contributions to oncogenesis). Oncogene. 1999;18:6094–6103
  93. Maehama T, Dixon JE. PTEN (A tumour suppressor that functions as a phospholipid phosphatase). Trends Cell Biol. 1999;9:125–128
  94. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat. 2000;16:109–122
  95. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res. 1999;253:210–229
  96. Leslie NR, Downes CP. PTEN (The down side of PI 3-kinase signaling). Cell Signal. 2002;14:285–295
  97. Stambolic V, Suzuki A, de la Pompa JL, et al.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39
  98. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene (A tumor suppressor with lipid phosphatase activity). J Natl Cancer Inst. 1999;91:1922–1932
  99. Zhou XP, Loukola A, Salovaara R, et al.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002;161:439–447
  100. Eng C. Genetics of Cowden syndrome (Through the looking glass of oncology). Int J Oncol. 1998;12:701–710
  101. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22
  102. Shields JM, Pruitt K, McFall A, et al.  Understanding Ras (“It ain’t over” “til it’s over”). Trends Cell Biol. 2000;10:147–154
  103. Zuber J, Tchernitsa OI, Hinzmann B, et al.  A genome-wide survey of RAS transformation targets. Nat Genet. 2000;24:144–152
  104. Reuther GW, Der CJ. The Ras branch of small GTPases (Ras family members don’t fall far from the tree). Curr Opin Cell Biol. 2000;12:157–165
  105. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131–136
  106. Eferl R, Ricci R, Kenner L, et al.  Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003;112:181–192
  107. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol. 1998;10:262–267
  108. De Ruiter ND, Burgering BM, Bos JL. Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451. Mol Cell Biol. 2001;21:8225–8235
  109. Ries S, Biederer C, Woods D, et al.  Opposing effects of Ras on p53 (Transcriptional activation of mdm2 and induction of p19ARF). Cell. 2000;103:321–330
  110. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331
  111. Hainaut P, Hollstein M. p53 and human cancer (The first ten thousand mutations). Adv Cancer Res. 2000;77:81–137
  112. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer. 2001;1:68–76
  113. Hollstein M, Sidransky D, Vogelstein B, et al.  p53 mutations in human cancers. Science. 1991;253:49–53
  114. Donehower LA. The p53-deficient mouse (A model for basic and applied cancer studies). Semin Cancer Biol. 1996;7:269–278
  115. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–374
  116. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res. 2001;264:56–66
  117. Jacobs JJ, Kieboom K, Marino S, et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164–168
  118. Maestro R, Dei Tos AP, Hamamori Y, et al.  Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999;13:2207–2217
  119. Schmitt CA, McCurrach ME, de Stanchina E, et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13:2670–2677
  120. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev. 2000;10:94–99
  121. Esteller M, Sparks A, Toyota M, et al.  Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000;60:4366–4371
  122. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol. 1998;18:6457–6473
  123. Samuels-Lev Y, O’Connor DJ, Bergamaschi D, et al.  ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001;8:781–794
  124. Bergamaschi D, Samuels Y, O’Neil NJ, et al.  iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 2003;33:162–167
  125. Kamimura A, Kamachi M, Nishihira J, et al.  Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 2000;89:334–341
  126. Hudson JD, Shoaibi MA, Maestro R, et al.  A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190:1375–1382
  127. Senoo M, Seki N, Ohira M, et al.  A second p53-related protein, p73L, with high homology to p73. Biochem Biophys Res Commun. 1998;248:603–607
  128. Osada M, Ohba M, Kawahara C, et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med. 1998;4:839–843
  129. Yang A, Kaghad M, Wang Y, et al.  p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305–316
  130. Trink B, Okami K, Wu L, et al.  A new human p53 homologue. Nat Med. 1998;4:747–748
  131. Kaghad M, Bonnet H, Yang A, et al.  Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–819
  132. De Laurenzi V, Melino G. Evolution of functions within the p53/p63/p73 family. Ann NY Acad Sci. 2000;926:90–100
  133. Strand S, Hofmann WJ, Hug H, et al.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—A mechanism of immune evasion?. Nat Med. 1996;2:1361–1366
  134. Moller P, Koretz K, Leithauser F, et al.  Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 1994;57:371–377
  135. Volkmann M, Schiff JH, Hajjar Y, et al.  Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med. 2001;79:594–600
  136. Muller M, Strand S, Hug H, et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99:403–413
  137. Maeda T, Yamada Y, Moriuchi R, et al.  Fas gene mutation in the progression of adult T cell leukemia. J Exp Med. 1999;189:1063–1071
  138. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997;89:1854–1861
  139. Straus SE, Jaffe ES, Puck JM, et al.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98:194–200
  140. Pitti RM, Marsters SA, Lawrence DA, et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703
  141. Cheng J, Zhou T, Liu C, et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759–1762
  142. Ugurel S, Rappl G, Tilgen W, et al.  Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001;7:1282–1286
  143. Shin MS, Kim HS, Lee SH, et al.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 2001;61:4942–4946
  144. Lee SH, Shin MS, Kim HS, et al.  Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 1999;59:5683–5686
  145. Nguyen T, Zhang XD, Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res. 2001;7(suppl):966s–973s
  146. Fisher MJ, Virmani AK, Wu L, et al.  Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res. 2001;7:1688–1697
  147. Irmler M, Thome M, Hahne M, et al.  Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–195
  148. Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt’s lymphoma. Blood. 1999;94:1727–1737
  149. Thome M, Schneider P, Hofmann K, et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997;386:517–521
  150. Hu S, Vincenz C, Ni J, et al.  I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-95-induced apoptosis. J Biol Chem. 1997;272:17255–17257
  151. Bertin J, Armstrong RC, Ottilie S, et al.  Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci USA. 1997;94:1172–1176
  152. Sturzl M, Hohenadl C, Zietz C, et al.  Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi’s sarcoma spindle cells. J Natl Cancer Inst. 1999;91:1725–1733
  153. Medema JP, Toes RE, Scaffidi C, et al.  Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur J Immunol. 1997;27:3492–3498
  154. Debatin KM, Poncet D, Kroemer G. Chemotherapy (Targeting the mitochondrial cell death pathway). Oncogene. 2002;21:8786–8803
  155. Chandra J, Mansson E, Gogvadze V, et al.  Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood. 2002;99:655–663
  156. Giraud S, Bonod-Bidaud C, Wesolowski-Louvel M, et al.  Expression of human ANT2 gene in highly proliferative cells (GRBOX, a new transcriptional element, is involved in the regulation of glycolytic ATP import into mitochondria). J Mol Biol. 1998;281:409–418
  157. Zamzami N, Susin SA, Marchetti P, et al.  Mitochondrial control of nuclear apoptosis. J Exp Med. 1996;183:1533–1544
  158. Weller M, Malipiero U, Aguzzi A, et al.  Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 1995;95:2633–2643
  159. Hermine O, Haioun C, Lepage E, et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996;87:265–272
  160. Campos L, Rouault JP, Sabido O, et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091–3096
  161. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992;52:5407–5411
  162. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 2000;6:1029–1035
  163. Findley HW, Gu L, Yeager AM, et al.  Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 1997;89:2986–2993
  164. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 2002;97:584–592
  165. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 1991;349:254–256
  166. Strasser A, Harris AW, Corcoran LM, et al.  Bcl-2 expression promotes B- but not T-lymphoid development in scid mice. Nature. 1994;368:457–460
  167. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440–442
  168. Takayama S, Sato T, Krajewski S, et al.  Cloning and functional analysis of BAG-1 (A novel Bcl-2-binding protein with anti-cell death activity). Cell. 1995;80:279–284
  169. Zeiner M, Gehring U. A protein that interacts with members of the nuclear hormone receptor family (Identification and cDNA cloning). Proc Natl Acad Sci USA. 1995;92:11465–11469
  170. Townsend PA, Dublin E, Hart IR, et al.  BAG-i expression in human breast cancer (Interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data). J Pathol. 2002;197:51–59
  171. Kudoh M, Knee DA, Takayama S, et al.  Bag1 proteins regulate growth and survival of ZR-75-1 human breast cancer cells. Cancer Res. 2002;62:1904–1909
  172. Sawitzki B, Amersi F, Ritter T, et al.  Upregulation of bag-1 by ex vivo gene transfer protects rat livers from ischemia/reperfusion injury. Hum Gene Ther. 2002;13:1495–1504
  173. Catlett-Falcone R, Landowski TH, Oshiro MM, et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–115
  174. Reed JC. The survivin saga goes in vivo. J Clin Invest. 2001;108:965–969
  175. Grossman D, McNiff JM, Li F, et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–1081
  176. Tanaka K, Iwamoto S, Gon G, et al.  Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127–134
  177. Kawasaki H, Altieri DC, Lu CD, et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–5074
  178. Satoh K, Kaneko K, Hirota M, et al.  Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271–278
  179. Hoffman WH, Biade S, Zilfou JT, et al.  Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–3257
  180. Grossman D, Kim PJ, Schechner JS, et al.  Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA. 2001;98:635–640
  181. Mesri M, Wall NR, Li J, et al.  Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981–990
  182. Dierlamm J, Baens M, Wlodarska I, et al.  The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93:3601–3609
  183. Rampino N, Yamamoto H, Ionov Y, et al.  Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967–969
  184. Meijerink JP, Mensink EJ, Wang K, et al.  Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood. 1998;91:2991–2997
  185. Panaretakis T, Pokrovskaja K, Shoshan MC, et al.  Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem. 2002;277:44317–44326
  186. Yin C, Knudson CM, Korsmeyer SJ, et al.  Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997;385:637–640
  187. Ionov Y, Yamamoto H, Krajewski S, et al.  Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA. 2000;97:10872–10877
  188. Soengas MS, Capodieci P, Polsky D, et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001;409:207–211
  189. Perkins C, Kim CN, Fang G, et al.  Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res. 1998;58:4561–4566
  190. Fu WN, Bertoni F, Kelsey SM, et al.  Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene. 2003;22:451–455
  191. Liston P, Fong WG, Kelly NL, et al.  Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol. 2001;3:128–133
  192. Teitz T, Wei T, Valentine MB, et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000;6:529–535
  193. Shivapurkar N, Toyooka S, Eby MT, et al.  Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther. 2002;1:65–69
  194. Baldwin AS. The NF-kappa B and I kappa B proteins (New discoveries and insights). Annu Rev Immunol. 1996;14:649–683
  195. Karin M, Cao Y, Greten FR, et al.  NF-kappaB in cancer (From innocent bystander to major culprit). Nat Rev Cancer. 2002;2:301–310
  196. Perkins ND. The Rel/NF-kappa B family (Friend and foe). Trends Biochem Sci. 2000;25:434–440
  197. Arlt A, Schafer H. NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther. 2002;40:336–347
  198. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis (Potentiation by inhibition of NF-kappaB). Science. 1996;274:784–787
  199. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221–227
  200. Webster GA, Perkins ND. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol. 1999;19:3485–3495
  201. Xiao G, Sun SC. Activation of IKKalpha and IKKbeta through their fusion with HTLV-I tax protein. Oncogene. 2000;19:5198–5203
  202. Ravagnan L, Gurbuxani S, Susin SA, et al.  Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol. 2001;3:839–843
  203. Jaattela M, Wissing D, Kokholm K, et al.  Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J. 1998;17:6124–6134
  204. Nylandsted J, Rohde M, Brand K, et al.  Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA. 2000;97:7871–7876
  205. Shresta S, Pham CT, Thomas DA, et al.  How do cytotoxic lymphocytes kill their targets?. Curr Opin Immunol. 1998;10:581–587
  206. Kagi D, Ledermann B, Burki K, et al.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369:31–37
  207. Heibein JA, Goping IS, Barry M, et al.  Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med. 2000;192:1391–1402
  208. Medema JP, de Jong J, Peltenburg LT, et al.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA. 2001;98:11515–11520
  209. Medema JP, Schuurhuis DH, Rea D, et al.  Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis (Differential modulation by T helper type 1 and type 2 cells). J Exp Med. 2001;194:657–667
  210. Igney FH, Krammer PH. Immune escape of tumors (Apoptosis resistance and tumor counterattack). J Leukoc Biol. 2002;71:907–920
  211. Igney FH, Behrens CK, Krammer PH. Tumor counterattack-concept and reality. Eur J Immunol. 2000;30:725–731
  212. Behrens CK, Igney FH, Arnold B, et al.  CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J Immunol. 2001;166:3240–3247
  213. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 1998;282:1714–1717
  214. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest. 1999;104:1655–1661
  215. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis (A link between cancer genetics and chemotherapy). Cell. 2002;108:153–164
  216. Zhu H, Fearnhead HO, Cohen GM. An ICE-like protease is a common mediator of apoptosis induced by diverse stimuli in human monocytic THP.1 cells. FEBS Lett. 1995;374:303–308
  217. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13:332–337
  218. Sherr CJ. The ink4a/arf network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2:731–737
  219. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–299
  220. Oda E, Ohki R, Murasawa H, et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053–1058
  221. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683–694
  222. Guan B, Yue P, Clayman GL, et al.  Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol. 2001;188:98–105
  223. Wu GS, Burns TF, McDonald ER, et al.  KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141–143
  224. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–310
  225. Bennett M, Macdonald K, Chan SW, et al.  Cell surface trafficking of Fas (A rapid mechanism of p53-mediated apoptosis). Science. 1998;282:290–293
  226. Fulda S, Meyer E, Friesen C, et al.  Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001;20:1063–1075
  227. Kidd JF, Pilkington MF, Schell MJ, et al.  Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002;277:6504–6510
  228. Robertson JD, Gogvadze V, Zhivotovsky B, et al.  Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem. 2000;275:32438–32443
  229. Friesen C, Herr I, Krammer PH, et al.  Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574–577
  230. Muller M, Strand S, Hug H, et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99:403–413
  231. Muller M, Scaffidi CA, Galle PR, et al.  The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw. 1998;9:685–686
  232. Eichhorst ST, Muller M, Li-Weber M, et al.  A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol. 2000;20:7826–7837
  233. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood. 2001;98:2603–2614
  234. Kasibhatla S, Brunner T, Genestier L, et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998;1:543–551
  235. Fulda S, Sieverts H, Friesen C, et al.  The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57:3823–3829
  236. Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA. 1997;94:8144–8149
  237. Eichhorst ST, Muerkoster S, Weigand MA, et al.  The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res. 2001;61:243–248
  238. Tolomeo M, Dusonchet L, Meli M, et al.  The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ. 1998;5:735–742
  239. Petak I, Tillman DM, Harwood FG, et al.  Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res. 2000;60:2643–2650
  240. Wieder T, Essmann F, Prokop A, et al.  Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood. 2001;97:1378–1387
  241. Nagane M, Pan G, Weddle JJ, et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 2000;60:847–853
  242. Keane MM, Ettenberg SA, Nau MM, et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999;59:734–741
  243. Fisher DE. Apoptosis in cancer therapy (Crossing the threshold). Cell. 1994;78:539–542
  244. Fulda S, Scaffidi C, Pietsch T, et al.  Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. 1998;5:884–893
  245. Fulda S, Susin SA, Kroemer G, et al.  Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 1998;58:4453–4460
  246. Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999;17:94–95
  247. Cole SP, Bhardwaj G, Gerlach JH, et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–1654
  248. Palissot V, Belhoussine R, Carpentier Y, et al.  Resistance to apoptosis induced by topoisomerase I inhibitors in multidrug-resistant HL60 leukemic cells. Biochem Biophys Res Commun. 1998;245:918–922
  249. Hirose M. Biology and modulation of multidrug resistance (MDR) in hematological malignancies. Int J Hematol. 2002;76(suppl 2):206–211
  250. Smyth MJ, Krasovskis E, Sutton VR, et al.  The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA. 1998;95:7024–7029
  251. Synold TW, Relling MV, Boyett JM, et al.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994;94:1996–2001
  252. Banerjee D, Mayer-Kuckuk P, Capiaux G, et al.  Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 2002;1587:164–173
  253. Simonsen CC, Levinson AD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA. 1983;80:2495–2499
  254. Srimatkandada S, Schweitzer BI, Moroson BA, et al.  Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J Biol Chem. 1989;264:3524–3528
  255. Leichman CG, Lenz HJ, Leichman L, et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15:3223–3229
  256. Peters GJ, Backus HH, Freemantle S, et al.  Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587:194–205
  257. Torres-Garcia SJ, Cousineau L, Caplan S, et al.  Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem Pharmacol. 1989;38:3122–3123
  258. Wang ZM, Chen ZP, Xu ZY, et al.  In vitro evidence for homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst. 2001;93:1473–1478
  259. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485–495
  260. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999;59:1391–1399
  261. Aas T, Borresen AL, Geisler S, et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–814
  262. Neri LM, Borgatti P, Tazzari PL, et al.  The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res. 2003;1:234–246
  263. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151–157
  264. Zhou P, Qian L, Kozopas KM, et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89:630–643
  265. Kaufmann SH, Karp JE, Svingen PA, et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91:991–1000
  266. Krajewski S, Blomqvist C, Franssila K, et al.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995;55:4471–4478
  267. Zaffaroni N, Pennati M, Colella G, et al.  Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002;59:1406–1412
  268. Tran J, Master Z, Yu JL, et al.  A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA. 2002;99:4349–4354
  269. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst. 1997;89:341–343
  270. Kim AH, Khursigara G, Sun X, et al.  Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001;21:893–901
  271. Bentires-Alj M, Barbu V, Fillet M, et al.  NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22:90–97
  272. Sethi T, Rintoul RC, Moore SM, et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis (A mechanism for small cell lung cancer growth and drug resistance in vivo). Nat Med. 1999;5:662–668
  273. Walczak H, Bouchon A, Stahl H, et al.  Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 2000;60:3051–3057
  274. Knight MJ, Riffkin CD, Muscat AM, et al.  Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene. 2001;20:5789–5798
  275. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001;8:1066–1075
  276. Sheikh MS, Burns TF, Huang Y, et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58:1593–1598
  277. Lacour S, Hammann A, Wotawa A, et al.  Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001;61:1645–1651
  278. Chinnaiyan AM, Prasad U, Shankar S, et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA. 2000;97:1754–1759
  279. Old LJ. Tumor necrosis factor (TNF). Science. 1985;230:630–632
  280. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452
  281. Kircheis R, Wightman L, Kursa M, et al.  Tumor-targeted gene delivery (An attractive strategy to use highly active effector molecules in cancer treatment). Gene Ther. 2002;9:731–735
  282. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al.  Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806–809
  283. Walczak H, Miller RE, Ariail K, et al.  Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–163
  284. Kim K, Fisher MJ, Xu SQ, et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res. 2000;6:335–346
  285. Ashkenazi A, Pai RC, Fong S, et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155–162
  286. Griffith TS, Chin WA, Jackson GC, et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998;161:2833–2840
  287. Siegmund D, Hadwiger P, Pfizenmaier K, et al.  Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med. 2002;8:725–732
  288. LeBlanc H, Lawrence D, Varfolomeev E, et al.  Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002;8:274–281
  289. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002;7:449–459
  290. Franco AV, Zhang XD, Van Berkel E, et al.  The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol. 2001;166:5337–5345
  291. Leverkus M, Sprick MR, Wachter T, et al.  Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol. 2003;23:777–790
  292. Liu Q, Gazitt Y. Potentiation of dexamethasone, taxol and Ad-p53-induced apoptosis by Bcl-2 anti-sense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood. 2003;101:4105–4114
  293. Wang JL, Zhang ZJ, Choksi S, et al.  Cell permeable Bcl-2 binding peptides (A chemical approach to apoptosis induction in tumor cells). Cancer Res. 2000;60:1498–1502
  294. Banker DE, Cooper JJ, Fennell DA, et al.  PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. Leuk Res. 2002;26:91–106
  295. Hardwick M, Fertikh D, Culty M, et al.  Peripheral-type benzodiazepine receptor (PBR) in human breast cancer (Correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol). Cancer Res. 1999;59:831–842
  296. Fantin VR, Berardi MJ, Scorrano L, et al.  A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell. 2002;2:29–42
  297. Shinoura N, Sakurai S, Asai A, et al.  Over-expression of APAF-1 and caspase-9 augments radiation-induced apoptosis in U-373MG glioma cells. Int J Cancer. 2001;93:252–261
  298. Srinivasula SM, Hegde R, Saleh A, et al.  A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410:112–116
  299. Fulda S, Wick W, Weller M, et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8:808–815
  300. Kanwar JR, Shen WP, Kanwar RK, et al.  Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2001;93:1541–1552
  301. Pennati M, Colella G, Folini M, et al.  Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest. 2002;109:285–286
  302. Yamamoto T, Manome Y, Nakamura M, et al.  Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer. 2002;38:2316–2324
  303. Schmitz M, Diestelkoetter P, Weigle B, et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000;60:4845–4849
  304. Bischoff JR, Kirn DH, Williams A, et al.  An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373–376
  305. Nemunaitis J, Swisher SG, Timmons T, et al.  Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000;18:609–622
  306. Seth P, Brinkmann U, Schwartz GN, et al.  Adenovirus-mediated gene transfer to human breast tumor cells (an approach for cancer gene therapy and bone marrow purging). Cancer Res. 1996;56:1346–1351
  307. Selivanova G, Ryabchenko L, Jansson E, et al.  Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol. 1999;19:3395–3402
  308. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene. 1995;11:933–939
  309. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8(suppl):55s–61s
  310. Adams J, Elliott PJ. New agents in cancer clinical trials. Oncogene. 2000;19:6687–6692
  311. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway (Involvement in tumor survival and progression). Proc Natl Acad Sci USA. 2000;97:3850–3855
  312. Hortobagyi GN, Ueno NT, Xia W, et al.  Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects (A phase I clinical trial). J Clin Oncol. 2001;19:3422–3433
  313. Yoo GH, Hung MC, Lopez-Berestein G, et al.  Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001;7:1237–1245
  314. Villaret D, Glisson B, Kenady D, et al.  A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck. 2002;24:661–669
  315. Mymryk JS. Tumour suppressive properties of the adenovirus 5 E1A oncogene. Oncogene. 1996;13:1581–1589
  316. Ueno NT, Bartholomeusz C, Herrmann JL, et al.  E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3. ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000;6:250–259
  317. Lamfers ML, Grill J, Dirven CM, et al.  Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002;62:5736–5742
  318. Opalka B, Dickopp A, Kirch HC. Apoptotic genes in cancer therapy. Cells Tissues Organs. 2002;172:126–132
  319. Sawyers CL. Research on resistance to cancer drug Gleevec. Science. 2001;294:1834; (letter)
  320. Sawyers CL, Hochhaus A, Feldman E, et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis (Results of a phase II study). Blood. 2002;99:3530–3539
  321. Farrow B, Mark Evers B. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun. 2003;301:50–53
  322. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151–6161
  323. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway (A rational, mechanism-based treatment for hematologic malignancies?). Blood. 2000;96:1655–1669
  324. Cox AD, Der CJ. Farnesyltransferase inhibitors (Promises and realities). Curr Opin Pharmacol. 2002;2:388–393
  325. Crooke ST. Potential roles of antisense technology in cancer chemotherapy. Oncogene. 2000;19:6651–6659
  326. Sebolt-Leopold JS, Dudley DT, Herrera R, et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810–816
  327. Mehren MM, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med. 2003;54:343–369
  328. Cobleigh MA, Vogel CL, Tripathy D, et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  329. Wakeling AE. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol. 2002;2:382–387
  330. de Bono JS, Rowinsky EK. Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull. 2002;64:227–254
  331. Shawver LK, Slamon D, Ullrich A. Smart drugs (Tyrosine kinase inhibitors in cancer therapy). Cancer. 2002;Cell 1:117–123
  332. Dalen H, Neuzil J. Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. Br J Cancer. 2003;88:153–158
  333. Bayon Y, Ortiz MA, Lopez-Hernandez FJ, et al.  Inhibition of IkappaB kinase by a new class of retinoid-related anticancer agents that induce apoptosis. Mol Cell Biol. 2003;23:1061–1074
  334. Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci USA. 2001;98:392–394
  335. Reid GK, Besterman JM, MacLeod AR. Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment. Curr Opin Mol Ther. 2002;4:130–137
  336. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med. 2002;8(suppl):32s–37s
  337. Schwartz GK. CDK inhibitors (Cell cycle arrest versus apoptosis). Cell Cycle. 2002;1:122–123
  338. Mitsiades N, Mitsiades CS, Richardson PG, et al.  Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101:4055–4622
  339. Almond JB, Cohen GM. The proteasome (A novel target for cancer chemotherapy). Leukemia. 2002;16:433–443
  340. Adams J, Palombella VJ, Sausville EA, et al.  Proteasome inhibitors (A novel class of potent and effective antitumor agents). Cancer Res. 1999;59:2615–2622
  341. Lopes UG, Erhardt P, Yao R, et al.  p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997;272:12893–12896
  342. Almond JB, Snowden RT, Hunter A, et al.  Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia. 2001;15:1388–1397
  343. Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol. 2002;29:17–20
  344. Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 1991;252:1657–1662
  345. Maloney DG, Grillo-Lopez AJ, White CA, et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195
  346. Witzig TE, White CA, Wiseman GA, et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–3803
  347. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer—The time of truth. Lancet Oncol. 2002;3:672–683
  348. Chi KN, Gleave ME, Klasa R, et al.  A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res. 2001;7:3920–3927
  349. Elbashir SM, Harborth J, Lendeckel W, et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498
  350. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA. 2002;99:1443–1448
  351. Borkhardt A. Blocking oncogenes in malignant cells by RNA interference—New hope for a highly specific cancer treatment?. Cancer Cell. 2002;2:167–168
  352. Zhao M, Beauregard DA, Loizou L, et al.  Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001;7:1241–1244
  353. Khan J, Wei JS, Ringner M, et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001;7:673–679
  354. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol. 2002;20:1932–1941
  355. Dhanasekaran SM, Barrette TR, Ghosh D, et al.  Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822–826
  356. Ross DT, Scherf U, Eisen MB, et al.  Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227–235
  357. Alizadeh AA, Eisen MB, Davis RE, et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  358. Perou CM, Sorlie T, Eisen MB, et al.  Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  359. van’t Veer LJ, Dai H, van de Vijver MJ, et al.  Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536

☆ Supported by the Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe/Dr Mildred Scheel-Stiftung, Tumorzentrum Heidelberg/Mannheim, the Medical Faculty of the University of Heidelberg, and the National Cancer Center, Bethesda, MD.

PII: S0093-7754(03)00568-2

doi: 10.1053/j.seminoncol.2003.11.006

Seminars in Oncology
Volume 31, Issue 1 , Pages 90-119 , February 2004

Article Tools

* Image Usage & Resolution